OVN
vs
S
S&P/ASX 300
OVN
Over the past 12 months, OVN has underperformed S&P/ASX 300, delivering a return of 0% compared to S&P/ASX 300's +2% growth.
Stocks Performance
OVN vs S&P/ASX 300
Performance Gap
OVN vs S&P/ASX 300
Performance By Year
OVN vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Oventus Medical Ltd
Glance View
Oventus Medical Ltd. develops oral appliances for the treatment of obstructive sleep disordered and snoring. The company is headquartered in Brisbane, Queensland. The company went IPO on 2016-07-19. The firm has two operating segments, which include Australia and North America. The Company’s O2Vent devices are designed for any patient that suffers from nasal congestion, obstruction and mouth breathing. Its O2Vent Optima devices allow airflow to the back of the mouth while maintaining an oral seal and stable jaw position, which avoids obstructions from the nose, soft palate and tongue. The Company’s ExVent is a valve accessory that fits into the open airway of the O2Vent Optima device to augment traditional oral appliance therapy by stabilizing the airway. The ExVent valve contains air vents that open fully on inhalation for unobstructed airflow. The O2Vent Optima is an alternative to continuous positive airway pressure (CPAP) for the treatment of obstructive sleep apnea.
